COST-EFFECTIVENESS OF LIXISENATIDE COMBINED WITH BASAL INSULIN VERSUS INSULIN REGIMENS FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY BASAL INSULIN IN CHINA

被引：0
|
作者：
Men, P. [1 ]
Qu, S. [2 ]
Luo, W. [2 ]
Li, C. [3 ]
Zhai, S. [1 ,4 ]
机构：
[1] Peking Univ, Hosp 3, Dept Pharm, Beijing, Peoples R China
[2] IQVIA, Shanghai, Peoples R China
[3] Sanofi, Shanghai, Peoples R China
[4] Peking Univ, Hlth Sci Ctr, Inst Drug Evaluat, Beijing, Peoples R China
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB60
引用
收藏
页码：S150 / S150
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of lixisenatide combined with basal insulin versus insulin regimens for the treatment of patients in China with type 2 diabetes mellitus inadequately controlled by basal insulin
    Men, Peng
    Qu, Shuli
    Luo, Wenting
    Li, Chaoyun
    Zhai, Suodi
    [J]. DIABETES-METABOLISM RESEARCH AND REVIEWS, 2018, 34
  • [2] Comparison of lixisenatide in combination with basal insulin vs other insulin regimens for the treatment of patients with type 2 diabetes inadequately controlled by basal insulin: Systematic review, network meta-analysis and cost-effectiveness analysis
    Men, Peng
    Qu, Shuli
    Luo, Wenting
    Li, Chaoyun
    Zhai, Suodi
    [J]. DIABETES OBESITY & METABOLISM, 2020, 22 (01): : 107 - 115
  • [3] LIXISENATIDE, BASAL INSULIN AND PREMIXED INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY ORAL ANTIDIABETIC DRUGS: NETWORK META-ANALYSIS AND COST-EFFECTIVENESS ANALYSIS
    Men, P.
    Qu, S.
    Li, C.
    Zhai, S.
    [J]. VALUE IN HEALTH, 2019, 22 : S150 - S150
  • [4] COMPARATIVE EFFICACY AND SAFETY OF LIXISENATIDE AND INSULIN REGIMENS IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY BASAL INSULIN: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
    Men, P.
    Qu, S.
    Luo, W.
    Liu, Y.
    Li, C.
    Zhai, S.
    [J]. VALUE IN HEALTH, 2018, 21 : S35 - S35
  • [5] Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes
    Ericsson, Asa
    Glah, Divina
    Lorenzi, Maria
    Jansen, Jeroen P.
    Fridhammar, Adam
    [J]. PLOS ONE, 2018, 13 (02):
  • [6] A SHORT-TERM COST-EFFECTIVENESS ANALYSIS OF INSULIN DEGLUDEC/INSULIN ASPART VERSUS INSULIN GLARGINE U100 AND INSULIN ASPART IN PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON BASAL INSULIN
    Zhou, L.
    Zhou, N.
    Hu, M.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S386 - S386
  • [7] CLINICAL AND COST-EFFECTIVENESS OF INSULIN DELIVERY WITH V-GO® DISPOSABLE INSULIN DELIVERY DEVICE VERSUS MULTIPLE DAILY INJECTIONS IN PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON BASAL INSULIN
    Lajara, Rosemarie
    Davidson, Jaime A.
    Nikkel, Carla C.
    Morris, Tracy L.
    [J]. ENDOCRINE PRACTICE, 2016, 22 (06) : 726 - 735
  • [8] IDEGLIRA VERSUS IGLARLIXI FOR PATIENTS WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES ON BASAL INSULIN: A LONG-TERM COST-EFFECTIVENESS ANALYSIS IN THE CZECH REPUBLIC
    Russel-Szymczyk, M.
    Parekh, W.
    Rychna, K.
    Pohlmann, J.
    Hunt, B.
    [J]. VALUE IN HEALTH, 2018, 21 : S130 - S131
  • [9] COST-EFFECTIVENESS OF IDEGLIRA VERSUS BASAL-BOLUS INSULIN INTENSIFICATION REGIMENS IN PATIENTS WITH TYPE 2 DIABETES IN SLOVAK SETTING
    Psota, M.
    Racekova, N.
    Psenkova, M.
    Vandebrouck, T.
    Ramirez de Arellano, A.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A674 - A674
  • [10] Treatment Costs of Basal Insulin Regimens for Type 2 Diabetes Mellitus in France
    Detournay, Bruno
    Boultif, Zahra
    Bahloul, Amar
    Jeanbat, Viviane
    Robert, Julien
    [J]. PHARMACOECONOMICS-OPEN, 2021, 5 (02) : 211 - 219
12345